Free tool
FAERS Monitor: Epiduo Forte
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207917 or its brand name (Epiduo Forte, Adapalene, Benzoyl Peroxide). Reports on generic versions are filed under their own applications.
Reports
54
Serious
22
41% of reports
Hospitalization
9
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9
- rash6
- acne4
- erythema4
- application site pain3
- application site pruritus3
- burning sensation3
- pruritus3
- application site erythema2
- application site irritation2
- dermatitis atopic2
- drug hypersensitivity2
- drug interaction2
- dry skin2
- fluid retention2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 7 |
| 2020 | 7 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 10 |
| 2025 | 7 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site irritation | 2 | 62.6 | 16.1 | 68 |
| application site painSignal | 3 | 53.1 | 17.7 | 106 |
| application site pruritusSignal | 3 | 51.5 | 17.1 | 102 |
| application site erythema | 2 | 29.7 | 7.6 | 31 |
| acneSignal | 4 | 20.5 | 8.0 | 56 |
| burning sensationSignal | 3 | 16.7 | 5.5 | 30 |
| fluid retention | 2 | 15.3 | 3.9 | 14 |
| dermatitis atopic | 2 | 14.8 | 3.8 | 14 |
| erythemaSignal | 4 | 7.6 | 3.0 | 17 |
| dry skin | 2 | 5.8 | 1.5 | 4 |
| rashSignal | 6 | 5.4 | 2.5 | 18 |
| drug interaction | 2 | 4.9 | 1.3 | 3 |
| drug hypersensitivity | 2 | 4.0 | 1.0 | 2 |
| pruritus | 3 | 3.0 | 1.0 | 2 |
| drug ineffectiveSignal | 9 | 2.7 | 1.5 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.